(Section scheduled to be repealed on July 1, 2027)

Beginning on July 1, 2025, the State Employees Group Insurance Program shall provide coverage for all medically necessary FDA-approved treatments or medications prescribed to slow the progression of Alzheimer's disease or another related dementia, as determined by a physician licensed to practice medicine in all its branches. Coverage for all FDA-approved treatments or medications prescribed to slow the progression of Alzheimer's disease or another related dementia shall not be subject to step therapy. Any diagnostic testing necessary for a physician to determine appropriate use of these treatments or medications shall be covered by the State Employees Group Insurance Program. This Section is repealed on July 1, 2027.

(Source: P.A. 103-975, eff. 1-1-25; 104-1, eff. 6-9-25; 104-417, eff. 8-15-25.)